Type 2 Diabetes (T2D) is associated with defective ? cell insulin secretion and subsequent reductions of ? cell mass. Conventionally, apoptosis has been thought of as a major pathway to loss of ? cell mass in T2D. However, recent studies using rodent models have shown that dedifferentiation of mature ? cells into endocrine progenitor-like cells can also play a role in this process. Nevertheless, it remains unclear whether ? cell dedifferentiation is a key pathway in the pathogenesis of ? cell dysfunction in human T2D. The constraint stems from the limited ability to assess human T2D islets during disease progression. To address this question, I propose a combinatorial approach of single cell RNA sequencing (scRNA-Seq) using islets from human T2D donors, and computational regulatory network analysis to determine heterogeneity and hierarchy of human islet cells in T2D. In preliminary studies, I demonstrate the presence of unique ? cell subpopulations in T2D patients that do not exist in non-diabetic (ND) islets. These T2D-unique subpopulations are reminiscent of ? cell dedifferentiation found in rodents. Thus I propose two aims designed to determine the cellular identities of T2D-unique ? cell populations and underlying molecular mechanisms of ? cell fate change in T2D.
In Aim 1, I will characterize T2D- unique ? cell populations by experimental approaches such as RNA-FISH and examine functional differences between these cell populations by GSIS and/or intracellular Ca2+ microfluorimetry.
In Aim 2, I will determine the molecular mechanisms that lead to the generation of these unique populations from ND ? cells by using genetic manipulations of candidate TFs. I will inhibit TFs whose activity is significantly decreased in T2D-unique ? populations; and I will perform gain-of-function studies with TFs whose networks are predicted to be increased in T2D-unique ? subpopulations. This work will expand our knowledge of the evolution of ? cell failure in T2D using a system-based analysis of human islet cells. Ultimately, I aim to apply information gathered from this work to T2D drug discovery, by targeting key factors that regulate cell fate transition in human T2D. ! !

Public Health Relevance

s Dedifferentiation of mature ? cells into endocrine progenitor-like cells has been identified as a key pathway in the pathogenesis of ? cell dysfunction in rodents. Human Type 2 diabetes (T2D) islets also contain unique signatures of cell populations, reminiscent of ? cell dedifferentiation in rodents. This proposal aims to examine dedifferentiation of ? cells in human T2D islets and to determine the underlying mechanisms of this phenomenon in order to develop new approaches to treatment. !

National Institute of Health (NIH)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Postdoctoral Individual National Research Service Award (F32)
Project #
Application #
Study Section
Special Emphasis Panel (ZDK1)
Program Officer
Castle, Arthur
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Columbia University (N.Y.)
Internal Medicine/Medicine
Schools of Medicine
New York
United States
Zip Code